2 5-Piperazinedione Arnica Montana Whole Aspartic

證據等級: L5

預測適應症: 0 個

Multi-Ingredient Compound (2,5-Piperazinedione / Arnica Montana / Dopamine HCl et al.): Insufficient Data for Repurposing Evaluation

One-Sentence Summary

This candidate record contains a complex mixture of 18 substances — including botanical extracts, amino acids, excipients, and industrial chemicals — with no established therapeutic indication on file. The TxGNN model returned no predicted indications for this candidate, and no clinical trials or published literature were identified. Due to fundamental data gaps across all evaluation dimensions, a full repurposing assessment cannot be completed at this time.

Quick Overview

Item	Content
Original Indication	None on record
Predicted New Indication	None (TxGNN returned no predictions)
TxGNN Prediction Score	N/A
Evidence Level	Not assessable (no predictions, no studies)
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why This Evaluation Cannot Proceed

This candidate presents three compounding problems that prevent a standard repurposing analysis:

1. The “drug” is not a defined single entity. The INN field lists 18 disparate substances spanning botanical whole-plant extracts (Arnica montana, Chelidonium majus, Phytolacca americana, Strychnos nux-vomica), amino acids (Aspartic acid, Phenylalanine), a catecholamine (Dopamine HCl), sugars and excipients (Dextrose, Maltodextrin, Sucralose), and industrial/laboratory chemicals (Bisphenol A, Formaldehyde, Formic acid, Methyl alcohol, Nitric acid, Phosphoric acid). This composition pattern is consistent with a homeopathic or isopathic preparation rather than a conventional pharmaceutical; TxGNN’s knowledge graph is not designed to evaluate such mixtures.

2. No MOA data is available. Without a defined mechanism of action, it is impossible to reason about pharmacological plausibility for any new indication, nor to assess whether the predicted target space is biologically coherent.

3. TxGNN produced no output. The predicted_indications array is empty, meaning the model found no mappable drug–disease relationships in its knowledge graph for this candidate. This outcome is expected given that several ingredients (e.g., Bisphenol A, Formaldehyde) are not represented as therapeutic entities in DrugBank or the TxGNN disease ontology.

Safety Considerations

Please refer to the package insert for safety information.

Additionally, independent of regulatory status, several components in this mixture warrant flagging on general chemical safety grounds:

Bisphenol A — classified as an endocrine disruptor; not an approved therapeutic ingredient in any major regulatory jurisdiction.
Formaldehyde — a known human carcinogen (IARC Group 1); present in homeopathic preparations only at extreme dilutions, but the dilution level is not specified in this record.
Methyl alcohol (Methanol) — systemic toxin; use in pharmaceutical preparations is strictly regulated.
Strychnos nux-vomica seed — source of strychnine; narrow therapeutic index with significant toxicity risk.

No drug–drug interaction data was returned (DDI query status: not_found), and no Taiwan regulatory warnings are on file because no Taiwan license exists.

Conclusion and Next Steps

Decision: Hold

Rationale: TxGNN returned no predicted indications for this candidate, no regulatory authorizations exist in any jurisdiction, and multiple ingredients raise unresolved safety concerns. The data state does not support advancing to any repurposing evaluation stage.

To proceed, the following would be needed:

Clarify product identity: Determine whether this is a homeopathic formulation, an isopathic nosode, a laboratory reagent mixture, or a data entry error. The current ingredient list does not correspond to any recognizable pharmaceutical product class.
Establish dilution levels: If this is a homeopathic preparation, each ingredient’s dilution (e.g., 6X, 30C) must be specified to assess whether pharmacologically active concentrations are present.
Remove or justify non-therapeutic ingredients: Bisphenol A, Formaldehyde, Methyl alcohol, and industrial acids should not appear as active pharmaceutical ingredients; their presence must be explained before any safety review can begin.
Re-run TxGNN on individual active ingredients: If the intent is to repurpose a specific component (e.g., Dopamine HCl or an alkaloid from Nux vomica), each should be evaluated as a standalone entity with its own DrugBank ID.
Obtain MOA data: Query DrugBank or primary literature for any biologically active components before re-submitting for prediction.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.